Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
The present application provides imidazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
1. A compound which is:
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
3. The compound of claim 1 , which is:
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 , which is:
5. A pharmaceutical composition comprising a compound of claim 3 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
6. A pharmaceutical composition comprising a compound of claim 4 , and a pharmaceutically acceptable carrier.
7. The compound of claim 1 , which is:
or a pharmaceutically acceptable salt thereof.
8. The compound of claim 1 , which is:
9. A pharmaceutical composition comprising a compound of claim 7 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
10. A pharmaceutical composition comprising a compound of claim 8 , and a pharmaceutically acceptable carrier.
11. The compound of claim 1 , which is:
or a pharmaceutically acceptable salt thereof.
12. The compound of claim 1 , which is:
13. A pharmaceutical composition comprising a compound of claim 11 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
14. A pharmaceutical composition comprising a compound of claim 12 , and a pharmaceutically acceptable carrier.
15. The compound of claim 1 , which is:
or a pharmaceutically acceptable salt thereof.
16. The compound of claim 1 , which is:
17. A pharmaceutical composition comprising a compound of claim 15 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
18. A pharmaceutical composition comprising a compound of claim 16 , and a pharmaceutically acceptable carrier.
19. The compound of claim 1 , which is:
or a pharmaceutically acceptable salt thereof.
20. The compound of claim 1 , which is:
21. A pharmaceutical composition comprising a compound of claim 19 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
22. A pharmaceutical composition comprising a compound of claim 20 , and a pharmaceutically acceptable carrier.